Appropriate fluoroquinolone prescribing is important for patient safety.
Appropriate fluoroquinolone prescribing is important for patient safety.
CDC has been responding and coordinating with the Ministry of Health of the Democratic Republic of the Congo (DRC) since a new outbreak of Ebola in North Kivu province was reported on July 30, 2018.
CDC and public health and regulatory officials in several states are investigating a multistate outbreak of Salmonella Reading infections linked to raw turkey products.
CDC, several states, and the U.S. Food and Drug Administration are investigating a multistate outbreak of Shiga toxin-producing E. coli O157:H7 infections (STEC O157:H7) in 13 states.
CDC has updated the 2011 recommendations for use of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for treatment of latent TB infection.
CDC is investigating several multistate outbreaks of Salmonella infections linked to contact with live poultry in backyard flocks.
The Centers for Disease Control and Prevention (CDC) and state health departments are investigating hepatitis A outbreaks in multiple states among persons reporting drug use and/or homelessness and their contacts.
This Health Alert Network (HAN) Update provides current recommendations on management and reporting of Shigella infections that have been treated with ciprofloxacin or azithromycin and resulted in possible clinical treatment failure.
On May 8, 2018, the Ministry of Public Health (MoHP) of Democratic Republic of the Congo (DRC) declared an outbreak of Ebola virus disease (EVD) in Bikoro Health Zone, Equateur Province, in Northwest DRC.
A new rabies test developed at the Centers for Disease Control and Prevention (CDC) could mean people exposed to potentially rabid animals could forego the weeks-long regimen of shots to prevent the deadly disease.
Since the last update on April 16, 2018, 12 more ill people were added to this outbreak.
Herpes zoster, also known as shingles, is a common viral disease with about one million cases occurring each year in the United States. In October 2017, the Food and Drug Administration (FDA) approved a 2-dose, recombinant zoster vaccine ([RZV], Shingrix), for the prevention of herpes zoster in adults aged ≥50 years.